Loading...
menu
Search
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
Home
ETF
PDSB
PDSB
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
PDSB News
PDS Biotechnology Reports Positive Phase 2 Results for Cancer Therapy
Apr 16 2026
NASDAQ.COM
PDS Biotechnology's Cancer Therapy Trial Shows Promising Results
Apr 15 2026
stocktwits
PDS Biotechnology Reports 2025 Financial Results with Strategic Developments
Mar 31 2026
Yahoo Finance
PDS Biotechnology Corporation Q4 2025 Earnings Call Insights
Mar 30 2026
seekingalpha
PDS Biotechnology Reports FY 2025 Financial Results
Mar 30 2026
seekingalpha
PDS Biotechnology Set to Release FY Earnings
Mar 29 2026
seekingalpha
PDS Biotechnology Amends Phase 3 Trial Protocol for Accelerated Approval
Feb 20 2026
Newsfilter
Oncolytics Biotech Advances Pelareorep for Anal Cancer with 29% Response Rate
Jan 12 2026
PRnewswire
Oncolytics Biotech Advances Pelareorep for Anal Cancer with 29% Response Rate
Jan 12 2026
Newsfilter
PDS Biotech Submits Amended Protocol for VERSATILE-003 Trial, Potentially Accelerating PDS0101 Approval
Jan 09 2026
Newsfilter
PDS Biotechnology (PDSB) Receives Upgrade to Buy: Reasons Explained
Dec 08 2025
NASDAQ.COM
PDS Biotechnology Secures FDA Meeting to Discuss Accelerated Approval for PDS0101
Dec 02 2025
Newsfilter
VTI ETF Daily Update - November 20, 2025
Nov 20 2025
TipRanks
VTI ETF Update, October 6, 2025
Oct 06 2025
TipRanks
PDS Biotech Reveals Final Topline Survival Results from VERSATILE-002 Phase 2 Study in Head and Neck Cancer
Aug 25 2025
Newsfilter
Biotech Stocks Rally as Oncology Market Targets $866B by 2034
Aug 14 2025
Newsfilter
Show More News
